The term glioblastoma multiforme (GBM) refers to a grade IV astrocytoma based on the World Health Organization classification system. 1 This is a primary brain tumor of glial cell lineage (the astrocyte). These cells act as the supporting cells for the neurons of the central nervous system. Gliomas are graded based on the presence of 4 characteristics: mitoses, nuclear atypia, microvascular proliferation, and necrosis. The GBM has all 4 features. These tumors are the most common type of glial tumor with an annual incidence of approximately 3 to 4 per 100,000 in the United States. 2 There is a male predominance (3 male:2 female). Peak age of onset is in the 6th to 7th decade of life.
GBMs of late life are usually de novo or primary GBMs (not occurring as a result of progression of a lower grade glioma). Primary GBMs are associated with genetic changes including an overexpression of the epidermal growth factor receptor gene, p16 deletion, and mutations of phosphatase and tensin homologues. 3, 4 GBMs can occur in younger adults but usually develop from a lower grade tumor (secondary GBM). Peak age of onset is in the fourth to fifth decade of life. They are associated with an abnormality of TP53 and overexpression of platelet-derived growth factor A and PDGF receptor α. 2 These tumors are less common than primary GBMs.
The case presented here is of a 36-year-old woman. Therefore, this is likely a secondary GBM with a TP53 mutation. Secondary GBMs can occasionally be diagnosed on magnetic resonance imaging (MRI) if there is nonenhancing and enhancing areas of the mass (indicating lower and higher grades of tumor, respectively). In this case, the tumor was enhancing and cystic, signifying an area of necrosis. There was mass effect and midline shift, giving a clue as to the tumor's aggressive nature and rapid growth.
GBMs can occur anywhere in the central nervous system, although they develop mostly in the cerebral hemispheres in adults. The patient has a right frontal lobe tumor but complains of word-finding difficulties. No aphasia is mentioned on physical exam, and her handedness is not mentioned. This symptom is likely related to her general cognitive dysfunction since right cerebral hemispheric dominance is rare. The tumor's specific location is probably anterior to the premotor and motor strip since the patient has no motor deficits. Since damage to the anterior frontal lobe does not cause focal deficits, the tumor could have been present for years without any clinical symptomatology. A recent malignant transformation and rapid growth could have resulted in the clinical presentation of headaches secondary to high intracranial pressure and mass effect.
Symptoms due to high intracranial pressure and mass effect are treated with dexamethasone or other corticosteroids. In emergency circumstances, mannitol, other diuretics, and hyperventilation may be used. Surgical resection is the definitive treatment. Steroids are usually weaned off (as tolerated) following surgery. Some patients also demonstrate seizure activity resulting from their tumor or associated hemorrhage. Prophylactic antiepileptic medication is not recommended for patients who have brain tumors and no history of seizures. 5 GBMs are officially diagnosed via histopathology. Although they have a characteristic MRI appearance, metastatic tumors, abscesses, and low-grade tumors (pilocytic and pleomorphic xantho-astrocytoma) can be difficult to distinguish. Tissue for histopathology is procured by biopsy or surgical resection. Gross total resection (leaving < 1 cc of tissue behind) improves survival time. 6, 7 Currently, the standard of care for treatment is surgical resection followed by radiotherapy and chemotherapy. Radiotherapy consists of fractionated conformal external beam radiation to a total of 60Gray over 6 weeks. 8 This patient was given temozolomide concurrently with radiotherapy. Temozolmide is an alkylating chemotherapy that is delivered orally. It is approved by the Food and Drug Administration for use in anaplastic astrocytoma at relapse. 9 Standard dosing is 150 to 200 mg per m 2 per day, days 1 through 5 of each 28-day cycle. At least 6 cycles of temozolomide are recommended, although patients can tolerate > 4 years of treatment (William R. Shapiro, personal communication, 2003). Temozolomide has radiosensitizing properties; therefore, many neurooncologists start treatment on initiation of radiotherapy at 75 mg/m 2 every day for 6 weeks. 10 Dose-limiting toxicity is bone marrow suppression. Other common side effects include nausea, vomiting, constipation, and fatigue. This patient discontinued her use of oral contraceptives when she started temozolomide. This is not advisable. Even though many chemotherapies prohibit ovulation, patients have become pregnant while on this chemotherapy.
Generally, serial MRIs and neurological exams are used to determine treatment efficacy and durability. Usually, an MRI is performed preoperatively, postoperatively, a few weeks postradiation, and then every 2 to 3 months thereafter to screen for recurrence. Since many patients show radiological evidence of recurrence prior to clinical deterioration, MRI follow-up is essential.
Other chemotherapies have been used for GBM with fair results. Carmustine (BCNU) and PCV (procarbazine, CCNU, vincristine) are the most common alternatives. 11 Other agents such as thalidomide, tamoxifen, and retinoic acid have been used with limited benefits. 12, 13 Currently, some of these drugs have been used in combination with temozolomide, although no definite evidence exists to support this practice. There are numerous protocols open nationwide for patients with primary diagnosis or recurrent GBM using a variety of radiation, chemotherapies, and immunotherapies. 14 Unfortunately, there is no cure for this disease, and nearly 100% recur. Mean survival with treatment is 1 year.
This patient had no family history of cancer or toxic exposures. There are some genetic predispositions for GBM, although it is usually a sporadic occurrence. The only environmental factor yet implicated is ionizing radiation. Other factors such as cellular telephones, aspartame, and electromagnetic fields have been studied, but no causal relationship has been found. [15] [16] [17] 
